Multicenter 1-Year Observational Study of Patients Who Are Initiating Brivaracetam
Aims: The primary aim of this postmarketing, non-interventional study is to determine brivaracetam (BRV) retention (continuing treatment) in daily clinical practice over a 12-month observation period from the initiation of the medication. BRV will be prescribed according to normal clinical practice. BRV is indicated as adjunctive (add-on) therapy in the treatment of partial onset seizures with or without secondary generalization in patients 16 years of age and older with epilepsy.
Principal Investigator: Jaishree Narayanan, MD
NorthShore Project Number: EH17-366
Contact: Call 847.570.4224 with questions regarding the study